| Bioactivity | Acipimox (K-9321) sodium, a nicotinic acid analogue, is an antilipolytic compound. Acipimox sodium stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity[1][2][3]. |
| Invitro | Acipimox sodium (0-100 µM; 0-4 hours) enhances leptin release from adipocytes isolated from Sprague-Dawley rats in a time- and dose- dependent manner[2].Acipimox sodium (10 mM) stimulats leptin release in adipocytes from Streptozotocin (STZ)-treated and Zucker diabetic fat (ZDF) rats[2]. |
| In Vivo | Acipimox sodium (50 mg/kg; i.p.) significantly lowers circulating free fatty acid (FFA) and glucose in high-fat fed mice[3]. Animal Model: |
| Name | Acipimox sodium |
| CAS | 76958-97-9 |
| Formula | C6H5N2NaO3 |
| Molar Mass | 176.11 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Vestergaard ET, et, al. Short-term acipimox treatment is associated with decreased cardiac parasympathetic modulation. Br J Clin Pharmacol. 2017 Dec;83(12):2671-2677. [2]. Wang-Fisher YL, et, al. Acipimox stimulates leptin production from isolated rat adipocytes. J Endocrinol. 2002 Aug;174(2):267-72. [3]. Ahrén B. Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice. Acta Physiol Scand. 2001 Feb;171(2):161-7. |